MEETING PROSPECTUS www.virology-education.com

CONTENT Introduction... 3 Workshop description... 4 Background...4 Meeting Objectives...4 Learning Objectives...4 Format...4 Unique Meeting Features...4 Target audience...5 Demographics...5 Geographical distribution last meeting...5 Program Committee... 6 Participants Feedback 2013... 7 Personal benefits...7 Content...7 Lectures...8 Metrics 2013...10 Pre-workshop communications...10 Post-workshop communications...10 Most effective elements...11 Quotes...11 Summary...12 2

INTRODUCTION The Workshop on HCV Therapy Advances was initiated three years ago and has been designed to educate treating physicians and researchers on the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals in an interactive setting. The conference presentations by international key opinion leaders are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. Clinical case discussions are also an important part of the program, in order to stimulate interaction and allow discussions on local issues. This meeting prospectus is designed in order to provide information on the meeting set up, demographics and metrics and also on the evaluation scores from the 2013 workshop participants. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation. We would surely welcome your suggestions for improvement of this workshop in order to best serve the Hepatitis treating community in Europe. On behalf of the Program Committee, STEFAN ZEUZEM, MD JW Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute / University of Texas Health Science Center, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, The Netherlands 3

WORKSHOP DESCRIPTION BACKGROUND The entrance of HCV direct acting antivirals into routine clinical practices provides a great opportunity for improved care, but at the same time, substantial challenges for the treating physician. The Workshop on HCV Therapy Advances has been developed to educate treating physicians and researchers, to discuss the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals. The conference presentations and case discussions presented by international recognized experts in the field are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. MEETING OBJECTIVES The objective of this meeting is to create an interactive setting, in which key opinion leaders present and discuss the latest scientific data on clinical management of hepatitis infected patients. LEARNING OBJECTIVES After participating in this activity, the participants will: Have an understanding of the basic concepts of HCV therapy Be updated on the latest developments in the field of HCV antiviral research Have an understanding of the challenges of HCV treatment in different patient populations Have an overview of the advantages and possibilities of new antivirals in HCV therapy Know how to apply direct acting antivirals in clinical practice FORMAT This 1,5 day independent, scientific and educational workshop consists of invited lectures, round-table discussions and clinical case presentations. In order to ascertain an interactive workshop setting, much time is allocated to discussions. UNIQUE MEETING FEATURES The workshop is a unique European platform for clinicians and other professionals working in the field of viral hepatitis, translating new data into new treatment strategies to further improve clinical care The workshop attracts different disciplines involved in the field of HCV therapy The workshop includes the latest data presented at EASL, APASL and AASLD. The workshop stimulates European collaborations and networks The workshop stimulates updates on guidelines and encourages treatment efficiency 4

TARGET AUDIENCE Hepatologists Infectious disease doctors Gastroenterologists Other healthcare professionals involved in daily care of hepatitis patients Post-graduate students DEMOGRAPHICS 2013 Clinicians 71% Researchers 0% Marketing person 6% Post -graduate students 0% Other 24% TOTAL number of registrants 100 Returning participants 33,3% New participants 66,7% GEOGRAPHICAL DISTRIBUTION LAST MEETING Australia 1 Russia 1 Austria 1 Saudi Arabia 1 Belgium 14 Spain 3 Finland 4 Sweden 1 France 13 The Netherlands 8 Germany 6 United Kingdom 3 Italy 21 USA 4 Mexico 1 5

PROGRAM COMMITTEE STEFAN ZEUZEM, MD JW Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute / University of Texas Health Science Center, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, The Netherlands 6

PARTICIPANTS FEEDBACK 2013 PERSONAL BENEFITS This meeting improved my: Agree Neutral Disagree Medical or practical knowledge 100% 0% 0% Care attitudes 71,4% 28,6% 0% Procedural or cognitive skills 66,7% 33,3% 0% Practice behaviour 83,3% 16,7% 0% Patient s clinical outcomes 66,7% 16,7% 16,7 I would recommend this meeting to my colleagues: 86% I plan to attend this meeting again next year: 86% CONTENT Agree Neutral Disagree The content of the meeting met my expectations 85,7% 14,3% 0% Sufficient time allocated for discussion during the meeting 85,7% 14,3% 0% The allocated time per presentation was sufficient 85,7% 14,3% 0% I perceived no commercial bias at the meeting: 100% 7

PARTICIPANTS FEEDBACK 2013 LECTURES We are very proud of the evaluation of the invited lectures. Unfortunately Dr. Perno was not able to attend the meeting. FRIDAY, 13 DECEMBER Session 1: DAA s in combination with pegylated interferon and ribavine Boceprevir and telaprevir: efficacy and side effects, what have we learned in 2013 Fred Poordad, MD University of San Antonio Health Science Center, USA Novel DAA s combined with PEG/RIBA Heiner Wedemeyer, MD Hannover Medical School, Germany Content 100% 0% 0% Presentation 100% 0% 0% Content 100% 0% 0% Presentation 100% 0% 0% Session 2: DAA s in clinical development: what are the key A findings Simeprevir overview: From IFN-Containing to IFN-Free Regimens Maria Beaumont, MD Janssen Infectious Diseases Diagnostics BVBA, Belgium Content 100% 0% 0% Presentation 92,9% 7.1% 0% Session 3: Challenging Patient Populations Managing and monitoring of HCCi in the future era of DAA Massimo Colombo, MD University of Milan, Italy The current challenges in treating cirrhotic patients Marc Bourlière, MD Hôpital Saint Joseph, Marseille, France Content 80% 20% 0% Presentation 80% 20% 0% Content 80% 20% 0% Presentation 100% 0% 0% 8

SATURDAY, 14 DECEMBER Session 4: Genotype 2&3 and drug resistance Treating HCV genotype 2 & 3 Christophe Sarrazin, MD J.W. Goethe Hospital, Germany Drug resistance findings observed in clinical practice: implications for patient management Carlo Federico Perno, MD, PhD University of Rome Tor Vegata, Italy Latest insights from NUC- containing regimens: what is the best partner molecule? Geoffrey Dusheiko, MD UCL Institute for Liver and Health, Royal Free Hospital, UK Content 85,7% 14,3% 0% Presentation 100% 0% 0% Content Presentation Content 85,7% 14,3% 0% Presentation 85,7% 14,3% 0% Session 5: Interferon Free regimes NUC sparing regimens: where do we stand Stefan Zeuzem, MD J.W. Goethe Hospital, Germany Update: Early investigational trials Peter Ferenci, MD Medical University of Vienna, Austria Content 83,3% 16,7% 0% Presentation 100% 0% 0% Content 50% 50% 0% Presentation 50% 50% 0% 9

METRICS 2013 PRE-WORKSHOP COMMUNICATIONS Frequency/ Number Publicity through electronic newsletter 5 x per year / 4121 persons Flyers at other meetings Publicity on conference websites Invitations from industry Endorsements by the following two societies: - Italian Society for Infectious and Tropical Diseases - Italian Association for the Study of the Liver 4 meetings 30 websites yes used their databases for comunications Participants were asked how they heard about this activity. Below are the results: Percentage VE Newsletter 7% Invitation industry 47% VE Website 7% Internet research 13% Flyer at other meetings 0% Other conference agenda 7% Worth of mouth 20 % POST-WORKSHOP COMMUNICATIONS Workshop materials sent to workshop participants + participants previous years. Reviews in Antiviral Therapy & Infectious Diseases Frequency/Number +/- 250-300 persons 600 hard copy editions and online available on our workshop website (http://www. infectiousdiseasesonline.com/) Publications of presentations by industry 1 10

MOST EFFECTIVE ELEMENTS QUOTES The most effective element of this activity was the exchange of clinically relevant managing strategies Interesting discussion of both sessions and oral presentations. Lectures were of high level. Presentations were very informative for us who are not directly involved in the treatment of patients but still provide the analysis for the clinicians. The presentations followed by discussion. Clinical cases presentations and the discussions on this were very interesting and helpful for clinical practice. It s a good way to drive the discussion. 11

SUMMARY The Workshop on HCV Therapy Advances Meeting is a unique platform for sharing the most recent data and discussing the clinical application of these new antivirals in an interactive setting. The overall opinion of the meeting was very positive, as can be deducted from the above scores. As the vast majority of the audience consisted of clinicians, we can conclude that the aim of the meeting has been reached. Furthermore, delegates were satisfied with the scientific content of the workshop as well as with the format of the program. The format of this workshop has stimulated a high-level discussion among key opinion leaders and the expert faculty scored an average of 8.6 points for their lectures (on a scale of 1-10, 10 being excellent). Participants were also very pleased with the communication, logistics and content of the meeting. 86 % of the participants would recommend this workshop to their colleagues and more than 86% plans to attend this workshop again next year. Within one week after the meeting, the presentations were made available on the Virology Education website. The success and educational effect of this workshop have underlined the need for continuation. The Program Committee is pleased with the results of the 3 rd Workshop on HCV Therapy Advances and therefore looks forward to organizing the 4 th and 5 th edition of this workshop and welcoming old and new participants. The 4 th edition of the workshop will be held on 12-13 December 2014 in Paris, France and the 5 th edition will be held in Barcelona, Spain on 11-12 December 2015. 12